Session IV: Presentation of Selected Non-Colorectal Cancer Abstracts

SO-5: Tumor inflammation and proliferative status as biomarkers in gastroesophageal

Sarbajit Mukherjee

The study authors investigated in their study the use of targeted gene expression analysis in GEAC. It was revealed that inflammation in the tumor immune microenvironment is associated with improved overall survival and progression-free survival (when treated with ICI), regardless of BMI. They observed a significant association between cell proliferation and progression-free survival in overweight individuals who received immunotherapy. 


SO-6: Microarchitectural changes in regional lymph nodes after chemotherapy in oesophageal cancer - results from the UK MRC OE02 trial

Maximilian Kloft

The study authors present the first study to quantify the microarchitecture components in tumor negative lymph node (LNneg) of resectable oesophageal cancer (OeC) patients after chemotherapy compared to surgery alone. According to the authors, their results seem to suggest a switch from humoral to cell-mediated anti-tumor immunity in large LNneg. What is important to them is that the LN-based host anti-tumor response seems to be different after chemotherapy.


SO-7: The prognostic and predictive role of preoperative chemotherapy sensitivity in gastric adenocarcinoma: A study of national cancer database

Lei Deng

The study authors conclude that response to preoperative chemotherapy is both prognostic and predicts benefit from postoperative chemotherapy in gastric adenocarcinoma. Their findings need to be validated prospectively.


SO-8: Health-related quality of life (HRQoL) in patients treated with pembrolizumab for microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: results from the KEYNOTE-158 study

Michele Maio

The study authors conclude that pembrolizumab generally improved or preserved health-related quality of life in patients with previously treated MSI-H/dMMR advanced non colorectal solid tumors.


SO-9: Analysis of the immune-related (ir) endpoints of the mismatch repair–deficient (dMMR) non-endometrial solid cancers cohort from the GARNET study

Thierry André

The study authors conclude that dostarlimab - a humanized monoclonal antibody that binds the PD-1 receptor and blocks interaction with PD-L1 and PD-L2 - demonstrated durable antitumor activity by irRECIST per investigator assessment across multiple tumor types. The results were consistent with the primary endpoint, RECIST v1.1 by BICR analysis.


SO-10: An open-label, multi-centre, phase Ib/II study of PI3Kβ selective inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathway
Time Zone: CEST

Minkyu Jung

The study authors conclude that GSK2636771 - a potent, orally bioavailable, adenosine triphosphate-competitive selective inhibitor of PI3Kb with minimal off-target effects - combined with paclitaxel revealed manageable toxicities and antitumor activity in patients with PTEN-deficient advanced gastric cancer who progressed after first-line chemotherapy. The authors conclude that complete loss of PTEN expression may be associated with clinical benefits from GSK2636771 and paclitaxel. 


SO-11: KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – preliminary results from a Phase 1b study

Scott Kopetz

The study authors conclude that ATP128 - a single chimeric fusion protein composed of three elements essential to generate potent antitumoral cellular immunity - was well tolerated alone, as well as in combination with ezabenlimab - a humanized, monoclonal antibody targeting PD-1. Preliminary analyses indicate induction of ATP128-specific immune response observable in the peripheral circulation as well as increased infiltration of TILs into liver metastases.